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valuation of Four-Year Coronary
rtery Response After Sirolimus-Eluting Stent
mplantation Using Serial Quantitative Intravascular
ltrasound and Computer-Assisted Grayscale Value
nalysis for Plaque Composition in Event-Free Patients
iro Aoki, MD,* Alexandre C. Abizaid, MD, PHD, FACC,† Patrick W. Serruys, MD, PHD, FACC,*
ndrew T. L. Ong, MBBS, FRACP,* Eric Boersma, PHD,* J. Eduardo Sousa, MD, PHD, FACC,†
ico Bruining, PHD*
otterdam, the Netherlands; and São Paulo, Brazil
OBJECTIVES This study sought to evaluate the long-term arterial response after sirolimus-eluting stent
implantation.
BACKGROUND Sirolimus-eluting stents are effective in inhibiting neointimal hyperplasia without affecting
plaque volume behind the stent struts at six months.
METHODS Serial quantitative intravascular ultrasound and computer-assisted grayscale value analysis
over four years were performed in 23 event-free patients treated with sirolimus-eluting stents.
RESULTS In the first two years, the mean plaque volume (155.5  42.8 mm3 post-procedure and
156.8  57.7 mm3 at two years, p  0.86) and plaque compositional change expressed as
mean percent hypoechogenic tissue of the plaque behind the stent struts (78.9  8.6%
post-procedure and 78.2  8.9% at two years, p  0.67) did not significantly change.
However, significant plaque shrinking (change in plaque volume  18.4 mm3, p  0.02)
with an increase in plaque echogenicity (change in percent hypoechogenic tissue  7.8%,
p  0.0001) was observed between two and four years. The mean neointimal volume
increased over four years from 0 to 8.4  5.8 mm3 (p  0.0001). However, no further
statistically significant change occurred between two and four years (7.0  6.7 mm3 vs.
8.4  5.8 mm3, p  0.25).
CONCLUSIONS Between two and four years after sirolimus-eluting stent implantation, peri-stent tissue
shrank with a concomitant increase in echogenicity. These intravascular ultrasound findings
suggest that late chronic artery responses may evolve for up to four years after sirolimus-
eluting stent implantation. In addition, the fact that the neointima does not significantly
change from two to four years may suggest that the biological phenomenon of a delayed
healing response has begun to subside. (J Am Coll Cardiol 2005;46:1670–6) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.06.076American College of Cardiology Foundation
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lolymer-based drug-eluting stents reduce in-stent neointi-
al hyperplasia in randomized trials and registries (1–3).
owever, concern exists that the non-erodable polymer, as
ell as the presence of the drug within the polymer, may
xert long-term detrimental biological effects (4,5). Little
ata are available on long-term arterial responses after either
irolimus-eluting stent (SES) or paclitaxel-eluting stent
PES) implantation. A recent report showed that PES
mplantation was associated with an increase in plaque
olume behind the stent struts at six months (6). Although
ES do not affect the plaque volume behind the stent struts
t six months, no data at later time points have been
eported (7,8). The goal of this study was to evaluate the late
rogression of the intra-stent neointima as well as the
ong-term arterial remodeling process and changes in plaque
From the *Erasmus Medical Center, Rotterdam, the Netherlands; and the
Institute Dante Pazzanese of Cardiology, São Paulo, Brazil.p
Manuscript received December 9, 2004; revised manuscript received June 22, 2005,
ccepted June 28, 2005.omposition inside and outside the stent after SES implan-
ation. To investigate these changes, serial quantitative
ntravascular ultrasound (IVUS) and computer-assisted
rayscale value analyses for plaque compositional imaging
ver a four-year follow-up period were performed in event-
ree patients who were treated with SES.
ETHODS
tudy population. Thirty patients with de novo coronary
rtery lesions were treated with a single 18-mm sirolimus-
luting Bx-Velocity stent (Cordis, Miami Lakes, Florida) in
ão Paulo, Brazil, in the first human study of SES as
escribed elsewhere (9). After the procedure, proper risk
actor management was mandated for all patients. Of the 30
atients, 26 patients underwent IVUS examination at four
ears by protocol, three patients had target vessel revascu-
arization before scheduled four-year follow-up angiogra-
hy, and one asymptomatic patient refused repeat angiog-
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November 1, 2005:1670–6 Four-Year Arterial Response After SESaphy. Of these 26 patients, three were excluded: two
atients did not undergo IVUS at two-year follow-up, and
laque behind the stent on the immediate post-procedure
VUS could not reliably be assessed in one patient. Thus,
erial coronary angiography and intravascular ultrasound
nalysis were performed post-procedure, at four-month, one-
ear, two-year, and four-year follow-up in 23 patients who
ere event-free throughout the four-year follow-up period.
erial quantitative IVUS analysis. All follow-up IVUS
ere performed using an automated pull-back system at 0.5
m/s and recorded on VHS videotapes. Images were
igitized for quantitative analysis. The lumen, stent, and
xternal elastic membrane contours were detected with
URAD QCU analysis software (Curad B.V., Wijk bij
uurstede, the Netherlands) (7). The stented segment and
he 5-mm segments proximal and distal to the stent were
nalyzed. Over the four-year follow-up period, different
VUS catheters and ultrasound consoles were used. Post-
rocedure, four-month, and one-year follow-up, 20- or
0-MHz non–electrocardiogram (ECG)-gated IVUS were
erformed. At two-year follow-up, 30- or 40-MHz ECG-
r non–ECG-gated IVUS were performed. At four-year
ollow-up, 30- or 40-MHz non–ECG-gated IVUS were
erformed. Three IVUS consoles were used (In-Vision
Volcano Therapeutics, Rancho Cordova, California],
learview, and Galaxy [both Boston Scientific Corp.,
atick, Massachusetts]). To analyze and compare the IVUS
ata consistently, all IVUS examinations were retrospec-
ively ECG-gated using the Intelligate method, which
utomatically selects the end-diastolic frames from pre-
ecorded non–ECG-gated IVUS data (10). In addition, an
utomatic adjustment for 30-MHz Boston Scientific cath-
ters that were connected to a Clearview console was
pplied as previously described (11).
mage-based plaque characterization (echogenicity). We
sed a computer-aided, in-house–developed grayscale value
nalysis program for plaque characterization (12). Based on
he mean gray level (brightness) of the adventitia, plaque was
lassified as more (hyperechogenic) or less bright (hypoecho-
enic) in relation to the adventitia (Fig. 1A). The volume
ounded externally by the surface that lies 0.5 mm outside the
edia and internally by the surface that lies 0.2 mm outside the
edia was defined as the adventitia. In cross-sectional images,
t appears as a 0.3-mm thick band just outside the media.
pper tissue was defined as tissue that has a mean gray value
igher than the mean adventitial intensity plus two times its
Abbreviations and Acronyms
ANOVA  analysis of variance
ECG  electrocardiogram/electrocardiographic
IVUS  intravascular ultrasound
PES  paclitaxel-eluting stent
SES  sirolimus-eluting stenttandard deviation (12). Calcified plaque and stent struts 8ere in this upper tissue range. The percentage of hypo-
chogenic plaque was calculated for the entire region of
nterest, excluding upper tissue (Fig. 1B) (12).
tatistical analysis. Continuous variables were expressed
s mean values  standard deviations and compared by
eans of the paired t test. Overall IVUS parameters
volume and echogenicity) across all time points were
ompared using repeated-measure analysis of variance
ANOVA). Two post-hoc tests (between post-stent and
wo years, and between two years and four years) were
erformed with Bonferroni corrections (p value for signifi-
ance 0.025) for p values 0.05 on ANOVA.
ESULTS
atient characteristics. Mean age of patients was 57 years,
nd two-thirds were male (Table 1). The left anterior
escending artery was treated in 14 patients, right coronary
rtery in 6 patients, and left circumflex artery in 3 patients.
fter stent implantation, risk factor management was insti-
uted in all patients. Aspirin and statins were prescribed in
ll patients during the four years.
laque volume behind the stent struts. Table 2 shows the
erial quantitative IVUS data. Plaque volume behind the
tent struts did not change significantly in the first two years
p  0.86), but showed a significant change between two
nd four years because of a decrease in plaque volume
ehind the stent struts at four years (156.8  57.7 mm3 vs.
38.4  42.2 mm3, p  0.02). Although plaque volume
t the proximal edge of the stents increased significantly
t four-month follow-up compared with post-procedure
32.5  12.2 mm3 vs. 39.8  15.8 mm3, p  0.005), it did
ot differ significantly between post-procedure and four-
ear follow-up (32.5  12.2 mm3 vs. 33.0  11.7 mm3,
 0.81). At the distal edge, no significant changes in
laque volume were observed at any time point (p  0.18).
eointimal volume. Neointimal volume increased at each
easured time point, and was 8.4  5.8 mm3 at four-year
ollow-up (p  0.0001). Between post-procedure and two-
ear follow-up, a significant change in neointimal volume
as noted (0 mm3 vs. 7.0  6.7 mm3, p  0.0001).
owever, between two-year and four-year follow-up, the
ncrease in neointimal volume was not statistically different
7.0  6.7 mm3 vs. 8.4  5.8 mm3, p  0.25). Figure 2A
hows the correlation between neointimal volume and
laque volume behind the stent struts over four years.
laque composition. Serial computer-assisted grayscale
alue analyses for plaque composition are shown in Table 3.
ith respect to the plaque behind the stent struts, there was
significant decrease in percent hypoechogenic tissue, that
s, an increase in percent hyperechogenicity up to four years
p  0.0001). Between post-procedure and two years, there
ere no significant changes in plaque echogenicity (78.9 
.6% vs. 78.2  8.9%, p  0.67). However, between two
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Four-Year Arterial Response After SES November 1, 2005:1670–6nd four years, significant changes were noted (78.2 8.9%
s. 70.4  10.6%, p  0.0001). A similar pattern was
bserved for plaque at the proximal stent edge with a
ignificant reduction in percent hypoechogenic tissue at
our-year follow-up (p  0.02). At the distal stent edge, no
ignificant changes in plaque echogenicity were observed
igure 1. (A) The adventitia is defined as tissue outside the external elastic
tandard deviation are calculated. To observe the suitability, a normal di
reated. (B) Cross-sectional image of echogenicity and distribution graph o
reen. Hypoechogenic areas are colored red. ROI  region of interest.cross time points (p  0.78). Figure 3 is a representative cxample of a patient with plaque shrinkage and reduction of
ypoechogenic plaque composition from two-year to four-
ear follow-up.
eointimal echogenicity. The echogenicity of the neoin-
ima increased over the four-year follow-up period (p 
.0001) (Fig. 2B). On post-hoc testing with Bonferroni
brane contour. For all non-shadowed adventitia pixels, the mean value and
tion curve based on the same mean and standard deviation histogram is
ue echogenicity behind the stent struts. Hyperechogenic areas are coloredmem
stribu
f plaqorrections, the decrease in hypoechogenicity between four
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November 1, 2005:1670–6 Four-Year Arterial Response After SESonths and two years was not significant (74.9  12.7% vs.
6.7  19.1%, p  0.03), but was significant between
wo-year and four-year follow-up (66.7  19.1% vs. 57.0 
2.6%, p  0.01).
ISCUSSION
revious reports have shown that SESs are effective in
nhibiting neointimal hyperplasia without affecting total
essel volume or plaque volume behind the stent struts at six
onths (7,8). In the present study, this pattern of tissue
rowth inhibition inside and outside the SES was main-
ained at two years. However, at four-year follow-up, a
ignificant negative remodeling (shrinking) of the plaque
ehind the stent struts with an increase in hyperechogenic-
ty was observed.
Several studies have shown that plaque echogenicity in
he carotid artery is related to the histologic components of
laques and that echolucency (low echogenicity) can predict
linical events (13,14). For coronary plaque studies, plaque
chogenicity has also been related to the histologic compo-
ents of plaque (15–17). Hyperechogenic tissue has been
hown to be associated with a predominance of dense
brous or elastic tissue, whereas hypoechogenic plaque was
orrelated with predominance of loose fibrous, lipid, or
ecrotic tissue. Recently, other analysis systems such as
VUS elastography, IVUS palpography, IVUS radiofre-
uency analysis (so-called virtual histology), and optical
able 1. Patient Characteristics
n  23
ge, yrs (mean  SD) 57  9
ale, % 65.2
ypertension, % 69.6
yperlipidemia, % 47.8
iabetes mellitus, % 26.1
amily history, % 30.4
urrent smoking, % 65.2
reated vessel
LAD, % 60.9
LCX, % 13.0
RCA, % 26.1
AD  left anterior descending artery; LCX  left circumflex artery; RCA  right
oronary artery.
able 2. Serial Three-Dimensional Intravascular Ultrasound Ana
After
Procedure 4 Mo 1 Yr
eointima, mm3 0 2.1  1.7 3.8 
laque (stented segment), mm3 155.5  42.8 160.4  60.4 153.5 
essel (stented segment), mm3 305.1  53.7 310.8  99.4 305.4 
laque (proximal edge), mm3 32.5  12.2 39.8  15.8 36.5 
essel (proximal edge), mm3 82.6  21.9 88.6  23.8 80.1 
laque (distal edge), mm3 26.2  15.4 28.6  11.1 28.6 
essel (distal edge), mm3 63.3  22.0 68.5  20.8 66.5 Repeated-measures analysis of variance (ANOVA) was performed among five periods. Pos
ears were performed with Bonferroni corrections (significant level of p value is 0.025).oherence tomography have been used to evaluate plaque
ulnerability and plaque composition (18–20). However,
hese methodologic approaches require prospective acquisi-
ion of data, for which their respective devices were not
vailable for human use at the time of initial assessment.
laque echogenicity analysis by computer-assisted grayscale
alue is currently the only method that has the potential to
nalyze plaque composition in a retrospective manner.
of Neointima and Plaque Volume
2 Yrs 4 Yrs
ANOVA*
p Value
Post Hoc After
Procedure to
2 Yrs
Post Hoc
2 to 4 Yrs
7.0  6.7 8.4  5.8 0.0001 0.0001 0.25
156.8  57.7 138.4  42.2 0.04 0.86 0.02
309.8  84.1 290.5  65.3 0.09 — —
37.4  13.0 33.0  11.7 0.006 0.03 0.05
82.6  22.1 78.3  21.6 0.001 0.98 0.10
31.1  13.4 25.8  11.3 0.18 — —
67.3  21.8 61.4  22.7 0.07 — —
igure 2. (A) Correlation between neointimal volume and plaque volume
ehind the stent struts over four years. (B) Correlation between neointimal
ercent hypoechogenicity and plaque percent hypoechogenicity behind the
tent struts over four years. Error bars indicate 95% confidence interval.lysis
3.3
61.6
83.8
11.9
17.2
14.0
26.3t hoc analysis between after the procedure and two years, and between two and four
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Four-Year Arterial Response After SES November 1, 2005:1670–6For SES, 80% of the drug load is eluted within 30 days of
tent implantation (1). However, concern has arisen about
ong-term biological reactions to the non-biodegradable
olymer (5). Long-term exposure to these polymers may
ause chronic inflammation. Complete natural healing (i.e.,
e-endothelialization and a reduction in proteoglycan con-
ent) may take three to six months after bare metal stent
mplantation (21). In this present study, plaque volume
ehind the stent struts decreased between two and four
ears, and this shrinkage was accompanied by a change in
laque echogenicity, suggestive of a change in plaque
omposition. This may indicate that the peri-stent area has
ndergone a slower healing process after SES implantation
hat results in a more fibrous content at four-year follow-up.
In animal experiments, it has been documented that the
xuberant proliferative process observed after stenting is
argely inhibited in the early stage with SES, but the normal
ealing process is also delayed with persistence of fibrin
eposition and inflammatory cells (22). In humans, one
tudy reported the histologic findings of atherectomy spec-
mens of restenotic lesions after implantation of a paclitaxel
erivative-eluting polymer stent in which persistent fibrin
ccumulation with smooth muscle cells and proteoglycan
nd collagen type III-rich matrix with inflammation was
able 3. Percent Hypoechogenic Tissue Component in the Plaqu
After
Procedure 4 Mo 1 Yr
eointima, % — 74.9  12.7 68.9  17.1
laque (stented segment), % 78.9  8.6 79.4  6.7 81.3  7.4
laque (proximal edge), % 88.7  6.9 87.2  6.5 87.1  6.0
laque (distal edge), % 86.1  9.8 86.8  6.0 87.0  10.4
Repeated-measures analysis of variance (ANOVA) was performed among five period
ears were performed with Bonferroni corrections (significant level of p value is 0.0
rocedure. ‡Post-hoc analysis was performed between four months and two years.
igure 3. A representative example of a patient with plaque composit
ross-sectional vessel image at (A) post-procedure, (B) four months, (C) on
ine indicates stent. Green line indicates media. Dense blue line inyperechogenic areas are colored green. Hypoechogenic areas are colored
ost-procedure, (B’) 85.3% at four months, (C’) 88.4% at one year, (D’) 84.2%bserved at 12 months (4,5). An autopsy performed on a
atient four years after SES implantation showed complete
ealing, indicating that the delayed healing response had
bated, concurring with our findings (23).
In this study, neointimal volume continued to increase
ver the four-year period. However, the increase between
wo and four years failed to reach statistical significance (7.0
s. 8.4 mm3, p  0.25), and the change in neointimal
olume between two years and four years was significantly
ess than between the post-procedure and two-year mea-
urements (1.4 vs. 7.0 mm3, p  0.04), which possibly
ndicates that the delayed tissue proliferation has subsided.
arter et al. (24) reported long-term effects of SES in a
orcine coronary model. They found that inhibition of
eointimal hyperplasia was not sustained at 90 days com-
ared with the bare metal stent, and the mean neointimal
rea was similar between 90 days and 180 days. These
esults differ from observations seen in clinical trials, includ-
ng this study. Several trials have reported low target vessel
evascularization rates up to three years (25). This discrep-
ncy is likely explained by different monocyte and lympho-
yte responses to similar concentrations of sirolimus in
uman and porcine vessels, and the different anatomical
d Neointima
2 Yrs 4 Yrs
ANOVA*
p Value
Post Hoc After
Procedure to
2 Yrs
Post Hoc
2 to 4 Yrs
.7  19.1 57.0  22.6 0.0001† 0.03‡ 0.01
.2  8.9 70.4  10.6 0.0001 0.67 0.0001
.7  7.9 81.7  9.3 0.02 0.67 0.008
.5  9.5 85.9  9.4 0.78 — —
t-hoc analysis between after the procedure and two years, and between two and four
Repeated-measures ANOVA was performed among four periods, except after the
changes between two-year and four-year follow-up. Top row shows
r, (D) two years, and (E) four years. Red line indicates lumen. Light blue
s adventitia. Bottom row shows cross-sectional echogenicity images.e an
66
78
87
88
s. Posional
e yea
dicatered. (A’) Percent plaque behind stent hypoechogenicity was 84.0%
at two years, and (E’) 74.8% at four years.
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November 1, 2005:1670–6 Four-Year Arterial Response After SESeatures of normal porcine coronary arteries versus athero-
clerotic human coronary arteries (26).
Furthermore, the increase in neointimal echogenicity as
bserved in this study would also suggest that a fibrotic
rocess is now operative and predominant. The rate of
rowth of the neointima has slowed—both features suggest
hat the completion of the healing process may be expected
n the near future.
tudy limitations. This study is limited by the sample
ize of 23 patients. Secondly, patients without events
ere used for the serial IVUS analysis. Consequently,
hese results may not apply to all patients treated with
ES. Different IVUS catheters and consoles were used
ver the four-year period, and most data were acquired
ithout ECG gating. These differences may have ham-
ered the consistency of volumetric and echogenic anal-
sis (27). For instance, BSC 30-MHz catheters con-
ected to a Clearview console underestimates true
imensions (11). To correct for these discrepancies, the
esults from the 30-MHz catheter were adjusted using a
reviously reported mathematical model (11), and image
rtifacts resulting from cardiac cycle motion observed in
on–ECG-gated images were circumvented by the use of
he Intelligate method, which converts non–ECG-gated
ata to ECG-gated data retrospectively (10,28).
The adventitia was taken as a reference to determine the
hange in echogenicity occurring in the peri-stent and
ntrastent tissue. Any alterations to the adventitia (e.g.,
nflammatory and fibrotic reactions) after stent deployment
ay alter the echogenicity during the follow-up period.
ecause any potential increase in echogenicity of the adven-
itia cannot be totally excluded or measured, the change in
chogenicity of the peri-stent and intra-stent tissue may be
nderestimated and the interference of stent struts with
laque echogenicity may not be completely excluded. Fi-
ally, any remaining bias after correction from the use of
ifferent IVUS systems cannot be totally excluded in the
resent study. Despite the inherent limitations, plaque
chogenicity analysis by computer-assisted grayscale value is
o date the only method with the potential to analyze plaque
omposition retrospectively.
onclusions. After SES implantation, negative plaque
emodeling and a decrease of hypoechogenic plaque
omposition were observed at four-year follow-up. In
ddition, the fact that the neointima does not signifi-
antly change from two to four years may suggest that the
iological phenomenon of a delayed healing response has
egun to subside.
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